LEEI Consortium

 

9

 

Years of experience

3

 

Partners

1

 

Aim

 

Igniting a revolutionary era in modern vaccine production: Forging the path to a bold, cutting-edge vaccine manufacturing technology

 

The „LEEI Consortium“ brings together the dynamic partners of KyooBe Tech, Bausch+Ströbel, and four prestigious Fraunhofer Research Institutes in a thrilling interdisciplinary collaboration.

In a groundbreaking and forward-thinking methodology, we employ electron beams—supplanting hazardous chemicals—for the inactivation of pathogens. This revolutionary approach not only enhances production efficiency, but also elevates vaccine quality and ensures impeccable process reproducibility.

 

 

Harnessing the power of our interdisciplinary team, KyooBe Tech excels in driving process-oriented optimization, seamless system integration, and tailored market adaptation. Our expertise lies in taking revolutionary new technologies and elevate them to a market and industry availability. Elevating customer satisfaction through refined processes, seamless integration, and empowering businesses to thrive in todays dynamic markets.

 

B+S’s specializes in developing and manufacturing precision machines for pharmaceutical production. B+S lays a crucial foundation for upholding the stringent quality standards, which are mandated for pharmaceuticals, including vaccines. Their unparalleled expertise ensures the utmost precision and excellence in the manufacturing process, guaranteeing the highest quality products.

Four Fraunhofer institutes lead the scientific forefront of this technology, continuously innovating and exploring new applications of LEEI-technologies. They conduct extensive pathogen studies to identify potential vaccine candidates, while also spearheading the development of the prototype system.

In addition, the Bill & Melinda Gates Foundation invested USD 1.85 million for the second phase of the technology roadmap.

 

2012

The start of journey

First virus inactivation

2013

Design of large-scale tech innovation project

2013

Innovation project granted

 

Our journey

 
2012-01

The start of journey

First experiments, regarding Low-energy electron irradiation (LEEI), were performed by Fraunhofer cooperation of institutes FEP and IZI.

 
2012-01
 
2012-03

First virus inactivation

LEEI-based inactivation of viruses (PRRSV and Influenza A) by Fraunhofer institutes IZI and FEP.

 
2012-03
 
2013-01

Design of large-scale tech innovation project

Four Fraunhofer institutes (Fraunhofer FEP, IGB, IPA, IZI) are joining forces within in interdisciplinary research approach.

 
2013-01
 
2013-12

Innovation project granted

Project is founded by Fraunhofer innovation funds for 36 month period to speed up technology development and transfer. The focus of the project was set to examine the basic method of irradiating pathogen substances.

 
2013-12
 
2014-07

Filing of ELVIRA patent familiy

The technology is registered for a patent because of its novelty and uniqueness.

 
2014-07
 
2016-01

Grant by Bill & Melinda Gates Foundation

The Bill & Melinda Gates Foundation believes in potential of LEEI for vaccine manufacturing and finances a second project phase by USD 1.85 million. Fraunhofer FEP and Fraunhofer IPA jointly develope the basics of an automated irradiation system. This experimental base is installed at the Fraunhofer IZI in Leipzig by autumn 2018.

 
2016-01
 
2019-01-07

Licensing deal with Bausch+Ströbel

Cutting-edge technology needs excellent partners to foster their global distribution and applicability. Thus Fraunhofer and global partner for fill & finish Bausch+Ströbel joined forces in a strategic partnership.

 
2019-01-07
 
2020-01-02

Foundation of KyooBe Tech GmbH

KyooBe was founded as a spin-off by Bausch + Ströbel in order to make LEEI ready for pharmaceutical manufacturing. KyooBe brings together the know-how and the skills of a talented and highly diverse team.

 
2020-01-02
 
2022

Present ELLI 2.0 Prototype

Together with strong partners from science and practice, the technology is further developed and converted into a compact and scalable product prototype.

 
2022
 
2024

Market Access

The goal is to ensure the technological implementation and marketability of the manufacturing technology by that time.

 
2024
 

 
Participate in a new generation of vaccine manufacturing!

Get in contact to learn and participate!

Contact